Avita Medical announces Australia Medical Services Advisory Committee support

Avita Medical (RCEL) announced that Australia’s Medical Services Advisory Committee has recommended amendments to the Medicare Benefits Schedule to include the use of autologous skin cell suspension prepared with Recell for the treatment of severe acute burn wounds in adults and children. MSAC concluded that Recell is as safe and effective as traditional autologous skin grafting, while providing superior outcomes in donor site sparing and reducing the need for additional grafting procedures. MSAC further acknowledged that Recell can shorten hospital stays, ease patient pain, and minimize scarring. The MSAC recommendation supports the use of Recell for: adult patients with burns covering greater than or equal to 20% of total body surface area; pediatric patients with burns covering greater than or less than 10% TBSA and whole-of-face burn wound closure.